Serious adverse events experienced by patients with chronic heart failure taking spironolactone
Population
4 men with New York Heart Association functional class III chronic heart failure
Design
Case_series
Authors
Discussion
Loading...
Member takes
Implication
Hyperkalaemia risk with spironolactone in NYHA III HF, especially with diarrhoea, warrants monitoring; case series leaves incidence and predictors open.
Structured PICO
P
Population
4 men with New York Heart Association functional class III chronic heart failure
I
Intervention
Spironolactone added to conventional treatment
O
Outcome
Serious and occasionally fatal hyperkalaemiasafety
Spironolactone use in chronic heart failure can lead to severe hyperkalemia, particularly when complicated by diarrhea, necessitating close blood chemistry monitoring.
Cite This Study
Colin Berry (2001) studied this question.